VDyne, Inc. is developing the VDyne Transcatheter Tricuspid Valve Replacement System for the percutaneous treatment of tricuspid valve regurgitation. Tricuspid valve regurgitation is prevalent and carries an increased incidence of morbidity and mortality. The VDyne system is a “true-fit” design, specifically for the tricuspid valve. It’s novel side delivery approach is designed to facilitate simple femoral implantation and treat of a broad range of annular dimensions. This unique system has the opportunity to provide therapy to a largely untreated population of patients suffering with valve disease.
